aTYR PHARMA (ATYR) Enterprise Value (2019 - 2025)
aTYR PHARMA (ATYR) has disclosed Enterprise Value for 7 consecutive years, with -$78.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 9.08% year-over-year to -$78.9 million, compared with a TTM value of -$78.9 million through Dec 2025, down 9.08%, and an annual FY2025 reading of -$78.9 million, down 9.08% over the prior year.
- Enterprise Value was -$78.9 million for Q4 2025 at aTYR PHARMA, down from -$6.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$6.3 million in Q3 2025 and bottomed at -$116.5 million in Q3 2021.
- Average Enterprise Value over 5 years is -$81.0 million, with a median of -$79.7 million recorded in 2025.
- The sharpest move saw Enterprise Value crashed 239.31% in 2021, then skyrocketed 90.42% in 2025.
- Year by year, Enterprise Value stood at -$108.1 million in 2021, then skyrocketed by 38.64% to -$66.3 million in 2022, then plummeted by 48.29% to -$98.4 million in 2023, then grew by 26.48% to -$72.3 million in 2024, then dropped by 9.08% to -$78.9 million in 2025.
- Business Quant data shows Enterprise Value for ATYR at -$78.9 million in Q4 2025, -$6.3 million in Q3 2025, and -$80.5 million in Q2 2025.